Western Market Research predicts that the Global Oligonucleotide Synthesis Market was valued at USD 9,450.5 million in 2025 and is expected to reach USD 31,880.2 million by the year 2036, growing at a CAGR of 11.7% globally. This robust growth trajectory is underpinned by the unprecedented expansion of the biopharmaceutical sector, the rise of personalized medicine, and the critical role that synthetic nucleic acids play in cutting-edge research such as CRISPR gene editing and mRNA-based therapeutics.
Market Description
Oligonucleotide synthesis is the chemical process by which relatively short fragments of nucleic acids—either DNA or RNA—with a defined chemical structure are created. These "oligos" serve as the fundamental building blocks for modern biotechnology and molecular biology. From the primers used in basic PCR reactions to the complex antisense oligonucleotides used to treat rare genetic disorders, synthetic DNA and RNA are indispensable tools in the 21st-century laboratory.
The market has transitioned from a specialized, low-volume service into a high-throughput industrial powerhouse. While the traditional phosphoramidite method remains the industry standard, the market is currently witnessing a technological shift toward enzymatic synthesis, which promises to produce longer strands with higher purity and lower environmental impact. As the pharmaceutical industry moves away from small-molecule drugs and toward biologics, oligonucleotides have emerged as a unique class of "programmable" medicines. They can target specific genetic sequences to silence disease-causing proteins or correct splicing errors, offering hope for conditions that were previously considered untreatable. Furthermore, the rise of synthetic biology and the potential for DNA to be used as a high-density data storage medium are opening entirely new commercial frontiers for this market.
Global Oligonucleotide Synthesis Market Segmentation
The market is segmented by the complexity of the synthesis process, the scale of production, and the diverse applications across clinical and research settings.
By Type:
-
Research grade oligonucleotide synthesis: Focused on providing standard DNA/RNA primers and probes for routine laboratory work, including PCR, sequencing, and cloning. This segment relies on high-speed delivery and cost-efficiency.
-
High throughput DNA/RNA oligo synthesis: Utilizes advanced robotic platforms and microchip-based technologies to synthesize thousands of different sequences simultaneously. This is critical for screening libraries, synthetic biology, and large-scale genomic studies.
-
Specialty long oligonucleotide synthesis: Involves the creation of highly complex, long-chain nucleic acids (often exceeding 100-200 bases) with high fidelity. These are essential for gene assembly, CRISPR-Cas9 guide RNAs, and high-end therapeutic research.
By Application:
-
Therapeutic Applications: The highest-value segment, encompassing antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and aptamers used in drug development for oncology, neurology, and rare diseases.
-
Diagnostic Applications: Involving the production of highly specific probes and primers for molecular diagnostic kits, including those used for infectious disease testing and companion diagnostics in oncology.
-
Research and Academic Applications: Supporting basic life sciences research, drug target discovery, and the development of new biotechnological tools.
-
Synthetic Biology: Utilizing synthetic oligos to engineer new biological parts, pathways, and organisms for industrial and medical purposes.
Top Key Players Covered in Oligonucleotide Synthesis Market
The market features a mix of massive integrated life science companies and specialized contract manufacturing organizations (CMOs) that focus on high-purity synthesis.
-
Agilent Technologies
-
Biosearch Technologies, Inc (LGC Group)
-
Eurogentec (Kaneka Corporation)
-
GeneDesign, Inc. (Ajinomoto Co.)
-
Bio-Synthesis - CRO/CMO Life Sciences Company
Market Dynamics (DROT Analysis)
Drivers:
A primary driver is the rapid advancement of genomic research and the plummeting cost of DNA sequencing, which creates a proportional demand for synthetic oligos to act as primers and probes. The success of mRNA vaccines during the pandemic has also validated nucleic acid technology on a global scale, leading to a surge in investment for RNA-based therapies. Additionally, the increasing prevalence of chronic diseases and the move toward precision medicine—where treatments are tailored to a patient’s specific genetic profile—rely heavily on the availability of custom-synthesized oligonucleotides.
Restraints:
The market faces restraints in the form of technical limitations regarding the length and purity of synthesized strands. As oligos get longer, the cumulative error rate in chemical synthesis increases, leading to lower yields and higher purification costs. Furthermore, the high capital expenditure required to set up high-throughput or GMP-certified (Good Manufacturing Practice) synthesis facilities acts as a barrier to entry for smaller players and can keep the cost of specialized oligos high for researchers.
Opportunities:
The emergence of enzymatic DNA synthesis is a significant opportunity. Unlike chemical synthesis, enzymatic methods do not require harsh solvents and can potentially produce much longer sequences, which would revolutionize gene synthesis. There is also a massive opportunity in the developing field of DNA data storage, where massive amounts of digital information are encoded into synthetic DNA strands for long-term archiving. Expansion into emerging markets in the Asia-Pacific region, where biotech investment is surging, also offers significant growth potential.
Threats:
Regulatory hurdles are a constant threat, particularly for therapeutic oligos. Stringent FDA and EMA requirements for purity, stability, and delivery mechanisms can delay product launches. Additionally, the market is highly susceptible to intellectual property (IP) disputes, as the sequences and chemical modifications used in therapeutic oligos are often protected by complex patents. Any shift in government funding for basic research can also impact the sales of research-grade oligos.
Value Chain Analysis
The value chain for oligonucleotide synthesis is a highly specialized sequence of chemistry and logistics:
-
Upstream (Raw Materials): Suppliers provide phosphoramidites (the building blocks), solid supports (like controlled-pore glass), and specialized solvents and reagents.
-
Midstream (Synthesis and Instrumentation): This involves the manufacturers of the automated synthesizers and the service providers who operate them. The synthesis occurs on a solid support where nucleotides are added one by one in a cyclic process.
-
Downstream (Purification and Analysis): Once synthesized, the oligo must be cleaved from the support and purified using techniques like HPLC (High-Performance Liquid Chromatography) or PAGE (Polyacrylamide Gel Electrophoresis). It is then quantified using UV spectrophotometry and verified via mass spectrometry.
-
End-User Integration: The final product is delivered to biopharma companies for drug formulation, diagnostic labs for test kits, or academic labs for research.
Impact of COVID-19
The COVID-19 pandemic had an unprecedented accelerative impact on the oligonucleotide synthesis market. Virtually every PCR-based diagnostic test for the SARS-CoV-2 virus required specific synthetic primers and probes, leading to a global surge in demand that stretched the capacity of major players like Biosearch Technologies and Agilent. More importantly, the pandemic proved the viability of large-scale RNA production for vaccines. This has led to a permanent increase in manufacturing infrastructure and a massive influx of capital into the oligo therapeutic pipeline, as companies now look to apply RNA technology to everything from influenza to cancer.
Regional Analysis
North America currently dominates the market, largely due to the presence of a robust biopharmaceutical industry, high research spending, and a concentration of key players in the U.S. Europe follows as a strong second, with countries like Germany and the U.K. leading in genomic research and diagnostic development. The Asia-Pacific region is the fastest-growing market, driven by significant government investments in biotechnology in China and India, along with a growing number of local startups focusing on gene and cell therapy. South America and the Middle East are emerging as players in the diagnostic segment as they modernize their clinical laboratory infrastructures.
Outlook
The outlook for the Global Oligonucleotide Synthesis Market through 2036 is one of sustained innovation and industrialization. The market will likely move toward "decentralized synthesis," where benchtop enzymatic synthesizers allow individual labs to print their own DNA on demand, similar to 3D printing. As therapeutic oligos move from rare disease treatments to more common indications like high cholesterol or cardiovascular disease, the volume of production will reach new heights. The convergence of AI-driven drug design and automated high-throughput synthesis will significantly shorten the time required to bring new nucleic acid therapies to market. Ultimately, the ability to write DNA as easily as we read it will position oligonucleotide synthesis as a cornerstone of the global bio-economy.
Explore more reports here-
https://westernmarketresearch.com
1. Market Overview of Oligonucleotide Synthesis
1.1 Oligonucleotide Synthesis Market Overview
1.1.1 Oligonucleotide Synthesis Product Scope
1.1.2 Market Status and Outlook
1.2 Oligonucleotide Synthesis Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Oligonucleotide Synthesis Historic Market Size by Regions
1.4 Oligonucleotide Synthesis Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Oligonucleotide Synthesis Sales Market by Type
2.1 Global Oligonucleotide Synthesis Historic Market Size by Type
2.2 Global Oligonucleotide Synthesis Forecasted Market Size by Type
2.3 Research grade oligonucleotide synthesis
2.4 High throughput DNA/RNA oligo synthesis
2.5 Specialty long oligonucleotide synthesis
3. Covid-19 Impact Oligonucleotide Synthesis Sales Market by Application
3.1 Global Oligonucleotide Synthesis Historic Market Size by Application
3.2 Global Oligonucleotide Synthesis Forecasted Market Size by Application
3.3 Application 1
3.4 Application 2
3.5 Other
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Oligonucleotide Synthesis Production Capacity Market Share by Manufacturers
4.2 Global Oligonucleotide Synthesis Revenue Market Share by Manufacturers
4.3 Global Oligonucleotide Synthesis Average Price by Manufacturers
5. Company Profiles and Key Figures in Oligonucleotide Synthesis Business
5.1 Agilent Technologies
5.1.1 Agilent Technologies Company Profile
5.1.2 Agilent Technologies Oligonucleotide Synthesis Product Specification
5.1.3 Agilent Technologies Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.2 Biosearch Technologies
5.2.1 Biosearch Technologies Company Profile
5.2.2 Biosearch Technologies Oligonucleotide Synthesis Product Specification
5.2.3 Biosearch Technologies Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.3 Inc
5.3.1 Inc Company Profile
5.3.2 Inc Oligonucleotide Synthesis Product Specification
5.3.3 Inc Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.4 Eurogentec
5.4.1 Eurogentec Company Profile
5.4.2 Eurogentec Oligonucleotide Synthesis Product Specification
5.4.3 Eurogentec Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.5 GeneDesign
5.5.1 GeneDesign Company Profile
5.5.2 GeneDesign Oligonucleotide Synthesis Product Specification
5.5.3 GeneDesign Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.6 Inc.
5.6.1 Inc. Company Profile
5.6.2 Inc. Oligonucleotide Synthesis Product Specification
5.6.3 Inc. Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
5.7 Bio-Synthesis - CRO/CMO Life Sciences Company
5.7.1 Bio-Synthesis - CRO/CMO Life Sciences Company Company Profile
5.7.2 Bio-Synthesis - CRO/CMO Life Sciences Company Oligonucleotide Synthesis Product Specification
5.7.3 Bio-Synthesis - CRO/CMO Life Sciences Company Oligonucleotide Synthesis Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Oligonucleotide Synthesis Market Size
6.2 North America Oligonucleotide Synthesis Key Players in North America
6.3 North America Oligonucleotide Synthesis Market Size by Type
6.4 North America Oligonucleotide Synthesis Market Size by Application
7. East Asia
7.1 East Asia Oligonucleotide Synthesis Market Size
7.2 East Asia Oligonucleotide Synthesis Key Players in North America
7.3 East Asia Oligonucleotide Synthesis Market Size by Type
7.4 East Asia Oligonucleotide Synthesis Market Size by Application
8. Europe
8.1 Europe Oligonucleotide Synthesis Market Size
8.2 Europe Oligonucleotide Synthesis Key Players in North America
8.3 Europe Oligonucleotide Synthesis Market Size by Type
8.4 Europe Oligonucleotide Synthesis Market Size by Application
9. South Asia
9.1 South Asia Oligonucleotide Synthesis Market Size
9.2 South Asia Oligonucleotide Synthesis Key Players in North America
9.3 South Asia Oligonucleotide Synthesis Market Size by Type
9.4 South Asia Oligonucleotide Synthesis Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Oligonucleotide Synthesis Market Size
10.2 Southeast Asia Oligonucleotide Synthesis Key Players in North America
10.3 Southeast Asia Oligonucleotide Synthesis Market Size by Type
10.4 Southeast Asia Oligonucleotide Synthesis Market Size by Application
11. Middle East
11.1 Middle East Oligonucleotide Synthesis Market Size
11.2 Middle East Oligonucleotide Synthesis Key Players in North America
11.3 Middle East Oligonucleotide Synthesis Market Size by Type
11.4 Middle East Oligonucleotide Synthesis Market Size by Application
12. Africa
12.1 Africa Oligonucleotide Synthesis Market Size
12.2 Africa Oligonucleotide Synthesis Key Players in North America
12.3 Africa Oligonucleotide Synthesis Market Size by Type
12.4 Africa Oligonucleotide Synthesis Market Size by Application
13. Oceania
13.1 Oceania Oligonucleotide Synthesis Market Size
13.2 Oceania Oligonucleotide Synthesis Key Players in North America
13.3 Oceania Oligonucleotide Synthesis Market Size by Type
13.4 Oceania Oligonucleotide Synthesis Market Size by Application
14. South America
14.1 South America Oligonucleotide Synthesis Market Size
14.2 South America Oligonucleotide Synthesis Key Players in North America
14.3 South America Oligonucleotide Synthesis Market Size by Type
14.4 South America Oligonucleotide Synthesis Market Size by Application
15. Rest of the World
15.1 Rest of the World Oligonucleotide Synthesis Market Size
15.2 Rest of the World Oligonucleotide Synthesis Key Players in North America
15.3 Rest of the World Oligonucleotide Synthesis Market Size by Type
15.4 Rest of the World Oligonucleotide Synthesis Market Size by Application
16 Oligonucleotide Synthesis Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Global Oligonucleotide Synthesis Market Segmentation
The market is segmented by the complexity of the synthesis process, the scale of production, and the diverse applications across clinical and research settings.
By Type:
-
Research grade oligonucleotide synthesis: Focused on providing standard DNA/RNA primers and probes for routine laboratory work, including PCR, sequencing, and cloning. This segment relies on high-speed delivery and cost-efficiency.
-
High throughput DNA/RNA oligo synthesis: Utilizes advanced robotic platforms and microchip-based technologies to synthesize thousands of different sequences simultaneously. This is critical for screening libraries, synthetic biology, and large-scale genomic studies.
-
Specialty long oligonucleotide synthesis: Involves the creation of highly complex, long-chain nucleic acids (often exceeding 100-200 bases) with high fidelity. These are essential for gene assembly, CRISPR-Cas9 guide RNAs, and high-end therapeutic research.
By Application:
-
Therapeutic Applications: The highest-value segment, encompassing antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and aptamers used in drug development for oncology, neurology, and rare diseases.
-
Diagnostic Applications: Involving the production of highly specific probes and primers for molecular diagnostic kits, including those used for infectious disease testing and companion diagnostics in oncology.
-
Research and Academic Applications: Supporting basic life sciences research, drug target discovery, and the development of new biotechnological tools.
-
Synthetic Biology: Utilizing synthetic oligos to engineer new biological parts, pathways, and organisms for industrial and medical purposes.
Top Key Players Covered in Oligonucleotide Synthesis Market
The market features a mix of massive integrated life science companies and specialized contract manufacturing organizations (CMOs) that focus on high-purity synthesis.
-
Agilent Technologies
-
Biosearch Technologies, Inc (LGC Group)
-
Eurogentec (Kaneka Corporation)
-
GeneDesign, Inc. (Ajinomoto Co.)
-
Bio-Synthesis - CRO/CMO Life Sciences Company
